The call presented a balanced picture: strong operational and commercial progress in consumables, reaction volumes, product innovation (notably FLEX APEX and Xenium), improved gross margin, and a materially stronger cash position were clear positives. Offsetting these wins were meaningful declines in instrument revenue, continued capital expenditure constraints, regional funding variability (notably the Americas), and pricing/mix considerations from lower-cost assays. Management reinstated cautious but constructive guidance for 2026 (flat-to-modest growth excluding settlements) and emphasized continued cost discipline.

Company Guidance

10x reinstated full‑year 2026 revenue guidance of $600–$625 million, which at the midpoint implies roughly 0–4% growth versus 2025 after excluding $44 million of upfront patent‑settlement revenue from 2025’s $599 million; the guidance assumes continued double‑digit growth in single‑cell consumable reaction volumes and double‑digit spatial consumables revenue, while constrained CapEx will keep instrument revenue under pressure. Management also expects Q1 to be a larger share of full‑year revenue (historically ~23% of revenue, now about ~24% at the midpoint) and emphasized sustaining the cost discipline that helped end 2025 with $523 million in cash, up ~$130 million year‑over‑year.

Quarterly and Full-Year Revenue Performance

Q4 revenue of $166,000,000 (up 1% year-over-year) exceeded the high end of guidance; full-year revenue closed at $599,000,000 excluding $44,000,000 of upfront patent litigation settlement revenue.

Strengthened Balance Sheet and Cash Position

Ended the year with $523,000,000 in cash, cash equivalents, and marketable securities, an increase of $130,000,000 versus 2024, driven by disciplined cost management.

Consumables and Reaction Volume Momentum

Total consumables revenue in Q4 grew 6% year-over-year; single cell consumables grew 3% in Q4. Full-year reaction volumes increased 22% year-over-year, and Q4 saw strong reaction-volume growth (30%+) driven by new product adoption.

Spatial (Xenium) Growth and Utilization

Spatial consumables delivered double-digit revenue growth for the year driven by Xenium momentum; Xenium reactions reached 14,500 for the year, up approximately 34% year-over-year, with expanding customer utilization and fleet expansion.

FLEX APEX Product Launch and Adoption

Launched FLEX APEX (next-generation FLEX assay) in 2025; it became the most popular single cell assay by volume in Q4, offering lower cost per experiment and support for FFPE and fixed whole blood — enabling larger-scale AI and translational studies and driving incremental reaction volumes.

Spatial Platform Enhancements

Multiple spatial product launches in 2025 — Visium HD 3' and HD cell segmentation, and Xenium RNA+protein multimodal capability — materially expanded spatial capabilities and customer value.

Improved Gross Margin

Reported gross margin of 68% for 2025, up from 67% the prior year, helped by lower inventory write-downs and reduced royalty and warranty costs.

Operating Efficiency

Total operating expenses decreased 18% in the fourth quarter, primarily due to lower outside legal expenses and reduced personnel costs; management emphasized continued cost discipline going into 2026.

Reinstated Full-Year Guidance

2026 revenue guidance reinstated at $600,000,000 to $625,000,000 (which implies 0% to 4% growth over full-year 2025 excluding upfront settlements); guidance assumes continued double-digit growth for single cell reaction volumes and spatial consumables while CapEx remains constrained.

10x Genomics (TXG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TXG Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 06, 2026	2026 (Q1)	-0.27 / -	-0.28	―	―	―
Feb 12, 2026	2025 (Q4)	-0.20 / -0.13	-0.4	67.50% (+0.27)	―
Nov 06, 2025	2025 (Q3)	-0.29 / -0.22	-0.3	26.67% (+0.08)	―
Aug 07, 2025	2025 (Q2)	-0.37 / 0.28	-0.32	187.50% (+0.60)	―
May 08, 2025	2025 (Q1)	-0.47 / -0.28	-0.5	44.00% (+0.22)	―
Feb 12, 2025	2024 (Q4)	-0.30 / -0.40	-0.41	2.44% (<+0.01)	―
Oct 29, 2024	2024 (Q3)	-0.33 / -0.30	-0.79	62.03% (+0.49)
Aug 08, 2024	2024 (Q2)	-0.48 / -0.32	-0.53	39.62% (+0.21)	―
Apr 30, 2024	2024 (Q1)	-0.50 / -0.50	-0.44	-13.64% (-0.06)	―
Feb 15, 2024	2023 (Q4)	-0.35 / -0.41	-0.15	-173.33% (-0.26)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TXG Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 12, 2026	$17.51	$18.12	+3.48%
Nov 06, 2025	$13.00	$15.25	+17.31%
Aug 07, 2025	$12.80	$12.29	-3.98%
May 08, 2025	$8.63	$8.77	+1.62%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does 10x Genomics Inc (TXG) report earnings?

10x Genomics Inc (TXG) is schdueled to report earning on May 06, 2026, After Close (Confirmed).

What is 10x Genomics Inc (TXG) earnings time?

10x Genomics Inc (TXG) earnings time is at May 06, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TXG EPS forecast?

TXG EPS forecast for the fiscal quarter 2026 (Q1) is -0.27.